| Roche Pharma (Schweiz) AG - Tecentriq 840 mg/14 ml, Konzentrat zur Herstellung einer Infusionslösung |
| 66152 | | 02 | | Tecentriq 840 mg/14 ml | | Konzentrat zur Herstellung einer Infusionslösung | | L01FF05 | | | | 21.05.2019 | | |
|
| Composition |
| atezolizumabum 840 mg, histidinum, acidum aceticum glaciale, saccharum, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 14 ml. |
| Packungsbestandteile |
| Concentrate for infusion | | | | | | Active Agent | Dose |
|---|
| Atezolizumabum | 840mg / 14ml |
| | | | Inactive agents |
|---|
| Acidum Aceticum Glaciale | | Histidine | | Polysorbatum 20 | | Saccharum |
|
|
| Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 002 | | PR | PR | A | | Yes |
|
